Cue Biopharma Inc (CUE) News

Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements

Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while...

Form 8-K - Current report

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting

Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L...

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024

BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage...

Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference

BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage...